Press release
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growing Rapidly by - Illumina Inc., Guardant Health Inc., APIS Assay Technologies Ltd., Gencurix Inc., RainSure Scientific.
Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/esr1-mutated-metastatic-breast-cancer-diagnostics-market
The ESR1 Mutated Metastatic Breast Cancer Diagnostics market report majorly focuses on market trends, historical growth rates, technologies, and the changing investment structure. Additionally, the report shows the latest market insights, increasing growth opportunities, business strategies, and growth plans adopted by major players. Moreover, it contains an analysis of current market dynamics, future developments, and Porter's Five Forces Analysis.
ESR1 mutated metastatic breast cancer refers to a specific subtype of breast cancer where mutations occur in the ESR1 gene. This gene encodes for the estrogen receptor alpha (ERα), a key protein involved in estrogen signaling pathways within breast cells. Mutations in ESR1 can emerge during the course of breast cancer treatment, particularly in the metastatic stage. These mutations are linked to acquired resistance to hormonal therapies, including medications like tamoxifen and aromatase inhibitors. These therapies are designed to block estrogen receptor signaling, but ESR1 mutations can reduce their effectiveness, leading to challenges in managing metastatic breast cancer and requiring alternative treatment strategies.
Forecast Growth Projected:
The Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2030. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
List of the Key Players in the ESR1 Mutated Metastatic Breast Cancer Diagnostics Market: Illumina Inc., Guardant Health Inc., APIS Assay Technologies Ltd., Gencurix Inc., RainSure Scientific, NeoGenomics Inc., Sysmex Corporation, Asuragen Inc., CUSABIO TECHNOLOGY LLC and Cayman Chemical Company among others.
Segment Covered in the ESR1 Mutated Metastatic Breast Cancer Diagnostics Market:
By Test Type: NGS Based, PCR Based.
By Sample Type: Tissue, Plasma.
By End User: Oncology Centers, Diagnostic Centers, Cancer Research Institutes.
Regional Analysis:
The global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.
Get Customization in the report as per your requierments: https://datamintelligence.com/customize/esr1-mutated-metastatic-breast-cancer-diagnostics-market
Regional Analysis:
The global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The ESR1 Mutated Metastatic Breast Cancer Diagnostics Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications.
Chapter Outline:
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: key insights, key emerging trends, etc.
Chapter 3: Manufacturers competitive analysis, detailed analysis of ESR1 Mutated Metastatic Breast Cancer Diagnostics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 5 & 6: Revenue of ESR1 Mutated Metastatic Breast Cancer Diagnostics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: The main points and conclusions of the report.
Get a Free Sample PDF copy of the report @ https://datamintelligence.com/download-sample/esr1-mutated-metastatic-breast-cancer-diagnostics-market
FAQs
How big is the ESR1 Mutated Metastatic Breast Cancer Diagnostics Market?
The ESR1 Mutated Metastatic Breast Cancer Diagnostics Market size was USD $$$ 2023. It is expected to reach USD $$$ 2031.
How fast is the ESR1 Mutated Metastatic Breast Cancer Diagnostics Market growing?
The ESR1 Mutated Metastatic Breast Cancer Diagnostics Market will exhibit a HIGH CAGR during the forecast period, 2023-2031.
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growing Rapidly by - Illumina Inc., Guardant Health Inc., APIS Assay Technologies Ltd., Gencurix Inc., RainSure Scientific. here
News-ID: 3576198 • Views: …
More Releases from DataM Intelligence 4Market Research
United States Smart Agriculture Market is expected to reach USD 13.3 billion by …
Market Size and Growth:
The Global Smart Agriculture Market Size reached USD 22.6 billion in 2022 and is expected to reach USD 35.4 million by 2031, growing with a CAGR of 5.8% during the forecast period 2024-2031. The Market is growing due to increasing adoption of IoT, AI, and automation technologies in farming, aimed at improving crop yield, efficiency, and sustainability. According to DataM Intelligence
Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/smart-agriculture-market?sz
The…
United States Advanced Composites Market is expected to reach US$ 9.56 billion b …
Market Size and Growth:
The Global Advanced Composites Market Size reached US$ 35.3 billion in 2022 and is expected to reach US$ 78.8 billion by 2031, growing with a CAGR of 10.6% during the forecast period 2024-2031. The Market is growing due to increasing demand for lightweight, high-strength materials across aerospace, automotive, and construction industries, coupled with technological advancements in composite manufacturing. According to DataM Intelligence
Get a Free Sample Research PDF:…
United States Polyphenols-Rich Foods Market is expected to reach US$ 600 Million …
Market Size and Growth:
The Global Polyphenols-Rich Foods Market Size reached US$ 412.5 million in 2023 and is expected to reach US$ 719.42 million by 2031, growing with a CAGR of 7.2% during the forecast period 2024-2031. The Market is growing due to increasing consumer awareness of the health benefits of polyphenols, such as antioxidant and anti-inflammatory properties, driving demand for functional and natural foods. According to DataM Intelligence Report.
Get a…
United States Carbon Dioxide Monitor Market is expected to reach US$ 2.7 Billion …
Market Size and Growth:
The Global Carbon Dioxide Monitor Market Size reached US$ 7,800.45 million in 2024 and is expected to reach US$ 13,450.78 million by 2032, growing with a CAGR of 6.75% during the forecast period 2025-2032. The Market is growing due to increasing demand for indoor air quality monitoring and rising environmental regulations to control CO2 emissions.
Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/carbon-dioxide-monitor-market?sz
The Carbon Dioxide (CO2) Monitor Market refers…
More Releases for ESR1
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Set for Steady Growth A …
The global market for ESR1 mutated metastatic breast cancer diagnostics is projected to grow from USD 64.61 million in 2025 to USD 92.92 million by 2035, reflecting a compound annual growth rate (CAGR) of 3.7%, according to the latest market analysis. This growth trajectory is driven by the rising prevalence of ESR1 mutations in metastatic breast cancer patients, increasing demand for early and precise diagnostic solutions, and ongoing innovations in…
ESR1 mutated metastatic breast cancer Market Analysis 2034 - Competitive Landsca …
The ESR1-mutated metastatic breast cancer companies are AstraZeneca, Olema Pharmaceuticals, Arvinas, Sermonix Pharmaceuticals, Roche, Eli Lilly and Company, H3 Biomedicine, Eisai, Pfizer, Sun Pharma Advanced Research Company, Zenopharm, Daiichi Sankyo, and others.
ESR1-mutated metastatic breast cancer market, valued at approximately USD 1.3 billion in 2023, is projected to experience substantial growth during the forecast period (2024-2034). Furthermore, the US accounts for the largest market share, representing approximately 63% of the total…
United States ESR1 Mutated Metastatic Breast Cancer Diagnostics Market valuation …
"The global ESR1 mutated metastatic breast cancer diagnostics market size reached US$ 63.51 Million in 2024 from US$ 61.05 Million in 2023 and is expected to reach US$ 93.21 Million by 2033, growing at a CAGR of 4.4% during the forecast period 2025-2033." As per DataM intelligence research report
Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/esr1-mutated-metastatic-breast-cancer-diagnostics-market?sp
United States: Recent Industry Developments
✅ In September 2025, Guardant Health launched…
FDA Approves INLURIYO (Imlunestrant): A Game-Changer for ESR1-Mutated Metastatic …
The pharmaceutical landscape for metastatic breast cancer treatment has witnessed a significant milestone with the FDA approval of INLURIYO (imlunestrant) on September 25, 2025. Eli Lilly's innovative, world-first oral selective estrogen receptor degrader (SERD) represents the first endocrine therapy innovation specifically targeting ESR1 mutations in over two decades, addressing a critical unmet medical need in estrogen receptor-positive (ER+), HER2-negative breast cancer patients.
Image: https://www.abnewswire.com/upload/2025/09/ccb2e17e2f3a2721c027dabdf0f1bd92.jpg
The pharmaceutical landscape for metastatic breast cancer treatment…
ESR1-Mutated Metastatic Breast Cancer Market Set for Significant Growth by 2034, …
DelveInsight's "ESR1 Mutated Metastatic Breast Cancer - Market Insight, Epidemiology And Market Forecast - 2034" [https://www.delveinsight.com/report-store/esr1-mutated-metastatic-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr] report delivers comprehensive insights into the disease landscape, historical and forecasted epidemiology, as well as ESR1 Mutated Metastatic Breast Cancer market trends across the 7MM (United States, EU4 [Germany, France, Italy, and Spain], United Kingdom, and Japan). The report reveals that the ESR1-mutated metastatic breast cancer market, valued at approximately USD 1.3 billion in…
ESR1-Mutated Metastatic Breast Cancer Market Industry Analysis by Size, Share, G …
Introduction
The ESR1-Mutated Metastatic Breast Cancer Market focuses on a specific subtype of hormone receptor-positive (HR+), HER2-negative metastatic breast cancer characterized by mutations in the estrogen receptor 1 (ESR1) gene. These mutations confer resistance to standard endocrine therapies such as aromatase inhibitors, making the disease more difficult to manage and highlighting the need for novel targeted approaches.
In recent years, the emergence of oral selective estrogen receptor degraders (SERDs), next-generation endocrine therapies,…
